News & Media

LNC aims to develop the first Christensenella-based drug candidate for the treatment of obesity and metabolic disorders Bordeaux, October 15th, 2018 – LNC Therapeutics, a French biotech company specializing in gut microbiome-based drug discovery, today announced that it has signed an exclusive license agreement with Cornell University (Ithaca,...

+ Find out more

Bordeaux, October 1st, 2018 – LNC Therapeutics, a French biotech company specialized in the gut microbiome-based drug discovery, today announced the launch of a new clinical trial with Stablor®, OBEMINALE 2, and the treatment of the first patient. This new clinical study is intended to obtain 13.5 health claim from the European Food...

+ Find out more

LNC Therapeutics, a French biotechnology company specialized in research and development for gut microbiome-based drugs, is putting greater focus on its research on a new cluster of bacteria, christensenella, and its role in regulating the intestinal microbiome in various chronic metabolic diseases. LNC Therapeutics is the first company worldwide to...

+ Find out more

La connaissance de notre flore intestinale, de nos gènes et de notre cerveau laissent entrevoir de nouveaux traitements. Depuis les scandales de l'Isoméride et du Mediator, les pilules coupe-faim ont mauvaise réputation. Quelques molécules contre l'obésité sont disponibles aux Etats-Unis, mais leur efficacité reste limitée et elles n'ont...

+ Find out more

VivaTech is a festival of French and European technology, featuring a blend of big brands and tiny startups. We highlight six key trends this year: AI is on everyone’s mind AI is the buzzword of the moment and keeps popping up in conversation at every stand here in Paris. But not everyone agrees on what it is or how it’s best used. In...

+ Find out more